Abstract
Co-crystal is an attractive alternative and a new class of solid forms because that can be engineered to have desired physicochemical properties. Co-crystals have gained considerable attention from the generic pharmaceutical industry after the USFDA released its finalized guidlines in the year 2018 on the regulatory classification of co-crystals. In this review, we discussed how co-crystals could be explored as a potential alternative solid form for the development of a generic product that meets the legal, regulatory, and bioequivalence requirements. In the contents, we discussed in detail concepts such as the selection of coformers, various ways of making co-crystals, the strategy of characterization to discriminate between co-crystal and salt, polymorphism in co-crystals, the aspects of intellectual property and, finally, the regulatory aspects of co-crystals.
Keywords: Co-crystals, crystal engineering, generic pharmaceuticals, solid oral dosage form, regulatory perspective, polymorphism, solubility.
Recent Advances in Drug Delivery and Formulation
Title:Co-Crystals for Generic Pharmaceuticals: An Outlook on Solid Oral Dosage Formulations
Volume: 15 Issue: 1
Author(s): Maniyam Arun Pandian Rajendran*, Ravikiran Allada and Syed Shahnawaz Sajid
Affiliation:
- Research and Development Department, Novugen Pharma (Malaysia) Sdn. Bhd, Hicom-Glenmarie Industrial Park, Shah Alam 40150, Selangor,Malaysia
Keywords: Co-crystals, crystal engineering, generic pharmaceuticals, solid oral dosage form, regulatory perspective, polymorphism, solubility.
Abstract: Co-crystal is an attractive alternative and a new class of solid forms because that can be engineered to have desired physicochemical properties. Co-crystals have gained considerable attention from the generic pharmaceutical industry after the USFDA released its finalized guidlines in the year 2018 on the regulatory classification of co-crystals. In this review, we discussed how co-crystals could be explored as a potential alternative solid form for the development of a generic product that meets the legal, regulatory, and bioequivalence requirements. In the contents, we discussed in detail concepts such as the selection of coformers, various ways of making co-crystals, the strategy of characterization to discriminate between co-crystal and salt, polymorphism in co-crystals, the aspects of intellectual property and, finally, the regulatory aspects of co-crystals.
Export Options
About this article
Cite this article as:
Rajendran Arun Pandian Maniyam*, Allada Ravikiran and Sajid Shahnawaz Syed , Co-Crystals for Generic Pharmaceuticals: An Outlook on Solid Oral Dosage Formulations, Recent Advances in Drug Delivery and Formulation 2021; 15 (1) . https://dx.doi.org/10.2174/2667387815666210203151209
DOI https://dx.doi.org/10.2174/2667387815666210203151209 |
Print ISSN 2667-3878 |
Publisher Name Bentham Science Publisher |
Online ISSN 2667-3886 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential of Nanocarriers in Genetic Immunization
Recent Patents on Drug Delivery & Formulation Structural Characterization, Biological Effects, and Synthetic Studies on Xanthones from Mangosteen (Garcinia mangostana), a Popular Botanical Dietary Supplement
Mini-Reviews in Organic Chemistry Chemokines: Central Mediators of the Innate Response to Sepsis
Current Immunology Reviews (Discontinued) Gene Expression Profiling Analysis to Identify Key Genes and Underlying Mechanisms in Meniscus of Osteoarthritis Patients
Combinatorial Chemistry & High Throughput Screening Modifier Gene Studies to Identify New Therapeutic Targets in Cystic Fibrosis
Current Pharmaceutical Design Scorpion Extracts Inhibit Tumor Growth in Esophageal Cancer and Lung Adenocarcinoma
Current Signal Transduction Therapy Synthesis and Anti-tubercular Activity of 6-(<i>4</i>-Chloro/Methyl-phenyl)-4- Arylidene-4,5-dihydropyridazin-3(2<i>H</i>)-one Derivatives Against Mycobacterium tuberculosis
Letters in Drug Design & Discovery Cytokines as Regulators of Atherosclerosis in Murine Models
Current Drug Targets The Epidemiology and Health Effects of Tobacco Smoke Exposure
Current Pediatric Reviews Pentraxins and Atherosclerosis: The Role of PTX3
Current Pharmaceutical Design Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety The Role of T-Helper Cells in Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Recents Patents for Isolating, Delivering and Tracking Adult Stem Cells in Regenerative Medicine
Recent Patents on Drug Delivery & Formulation Frequencies of Single Nucleotide Polymorphisms in Cytochrome P450 Genes (CYP1A2, 2A6, 2B6, 3A4 and 3A5) in a Rwandan Population: Difference to Other African Populations
Current Pharmacogenomics and Personalized Medicine Phosphodiesterase 10 Inhibitors: New Disease Modifying Drugs for Parkinson’s Disease?
Current Medicinal Chemistry Current Nanotechnological Approaches for an Effective Delivery of Bioactive Drug Molecules to Overcome Drug Resistance Tuberculosis
Current Pharmaceutical Design Deciphering Role of Cytokines for Therapeutic Strategies Against Rheumatoid Arthritis
Current Drug Targets Flavonoids Acting on DNA Topoisomerases: Recent Advances and Future Perspectives in Cancer Therapy
Current Medicinal Chemistry New Antimicrobial Approaches: Reuse of Old Drugs
Current Drug Targets Synthesis, Docking and Antidiabetic Activity of Some Newer Benzamide Derivatives as Potential Glucokinase Activators
Letters in Drug Design & Discovery